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TregsThe negative role of the activated stimulator of IFN genes (STING) has been uncovered in autoinﬂammatory dis-
ease and cancer. However, the role of STING in virus-related carcinogenesis is not well known. Herein, HPV+
tongue squamous cell carcinoma (TSCC) (n = 25) and HPV− TSCC samples (n = 25) were randomly collected
and were veriﬁed by in situ hybridization (ISH) and p16 immunohistochemistry (IHC) to assess the expression
and activated status of STING through IHC. The results showed that the expression of STING was up-regulated
during the development of TSCC. Interestingly, although the expression of STING showed no difference between
HPV+/− TSCC samples, the activated status of STING with dark staining around the nucleus was observed in
HPV+ TSCC samples. The role of activated STINGwas analyzed in three cell lines by siRNA and indicated that ac-
tivated STINGhad no impact on cell viability or apoptosis but promoted the induction of several immunosuppres-
sive cytokines, e.g., IL-10, IDO and CCL22, which facilitated the inﬁltration of regulatory T cells (Tregs). Moreover,
increased inﬁltration of Foxp3+ Tregs along with increased expression of CCL22 was conﬁrmed in HPV+ TSCC
samples. An inhibitor of the MAPK/AP-1 pathway (U0126) and the silencing of c-jun signiﬁcantly suppressed
CCL22 induction and the recruitment of Tregs by activated STING. Furthermore, down-regulatedmiR-27was ver-
iﬁed in independent fresh TSCC samples (n= 50) and eight cell lines, which enhanced STING activation and led
to increased CCL22 expression for Tregs recruitment in the TSCCmicroenvironment. Therefore, our ﬁndings pro-
vided distinct insight into the side effects of activated STING in HPV-related carcinogenesis.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Stimulator of interferon genes (STING), also known as TMEM173, pre-
dominantly resides in the endoplasmic reticulum and mitochondrial-
associated membrane [1] and serves as a critical adaptor that detects
dsDNA from viral and eukaryotic pathogens as well as cyclic dinucleotide
(CDN) frombacteria [2]. Currently, CDNandhuman endogenousmessen-
ger 2′-5′, 3′-5′cyclic AMP-GMP (2′-3′cGAMP) have immunostimulatory
properties and are candidates for a vaccine adjuvant based on STING
activation [3]. 2′-3′cGAMP is generated by cyclic GMP-AMP synthase
(cGAS), which directly binds dsDNA. Once STING senses dsDNA or 2′-3′
cGAMP in the cytoplasm, it relocates to cytoplasmic punctate structures
around the nucleus and induces potent anti-viral genes and othertal of Stomatology and the State
of Immunology,Medical School,
aboratory of Pharmaceutical
l, Nanjing University, Nanjing
g), yayihou@nju.edu.cnproinﬂammatory cytokines to participate in anti-infection immunity or
autoimmune functions [4,5]. STING-associated vasculopathy with onset
in infancy (SAVI)was reported to be an autoinﬂammatory disease caused
by mutant STING, which was, clinically, a gain-of-function mutation [6].
Interestingly, an unexpected negative regulatory role for STING had
been reported in that STING could inhibit unchecked immune activation
during systemic lupus erythromatous (SLE), and STING-deﬁcient SLE
mice had signiﬁcantly increased autoantibody production and signiﬁ-
cantly reduced percentages of activated regulatory T cells (Tregs) cells
in axillary lymph nodes as well as shorter lifespans than controls [7].
However, the exact mechanism of the relationship between STING and
Tregs needs to be elucidated.
Recently, STING was reported to be a double-edged sword for non-
virus-related oncoimmunology [4,8,9]. On the one hand, in a colorectal
tumorigenesis mouse model, colons of STING-deﬁcient mice were sus-
ceptible to colitis-associated colorectal cancer and exhibited signiﬁcant
intestinal damage and proliferation during early stages of carcinogene-
sis [9]. On the other hand, STING was found to promote inﬂammation-
driven skin carcinogenesis by enhancing inﬂammatory cytokine levels
of the inﬁltrating phagocytes, but the STING−/−mice were resistant to
mutagen-induced skin carcinogenesis compared to wild-type mice [4].
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suppress experimental autoimmune encephalitis (EAE) in an IDO-
dependent manner, which implicated STING as being versatile in the
manipulation of the immune balance [10].
Human papillomaviruses (HPVs) are small double-stranded DNA
(dsDNA) viruses that infect squamous epithelia. Viral persistence
followed by HR-HPV infection, particularly HPV-16, 18, is a key risk fac-
tor for carcinogenesis [11]. Of note, because HPVs are difﬁcult to culture
in vitro and because of the insufﬁciency of mouse models, research on
the natural infection history of HPVs is very difﬁcult [12], and the
exact molecular evidence for the role of HPVs in relative cancers is lim-
ited. Other than its viral protein E6/7, many reports have indicated that
HPV infection could change the status of the host immune system [13].
High inﬁltration of Foxp3+ Tregs is often associated with an immuno-
suppressive microenvironment and promotes the progression of tu-
mors. A higher percentage of Foxp3+ Tregs was observed in HPV+
tonsillar cancer patients [14]. Badoual et al. showed that HPV+ head
and neck cancers were more heavily inﬁltrated by Foxp3+ Tregs [15],
and studies on cervical cancer also showed increasing levels of Foxp3
mRNA and Foxp3+ Tregs inﬁltration in HPV+ tumors with unclear mo-
lecular mechanisms [16,17].
New cancer statistics show that tongue squamous cell carcinoma
(TSCC) is still themost common oral cancer [18]. Although HPV integra-
tion is important for carcinogenesis, episomal HPV DNA has also been
detected in some carcinomas, suggesting that the episomesmay induce
malignant progression [19]. Thus, we hypothesized that HPV infection
could be sensed by DNA sensors to activate STING, contributing to the
inﬁltration of Foxp3+ Tregs and promoting the establishment and
maintenance of the TSCC microenvironment.2. Materials and methods
2.1. Patients and tissue samples
In this study, HPV+ TSCC samples (n= 25) andHPV− TSCC samples
(n= 25)were collected to assess the expression and activated status of
STING, and 50 fresh tissue samples collected from surgerywere used for
microRNA analysis. All of the patients diagnosed with primary TSCC
were conﬁrmed by hematoxylin and eosin staining by experienced
pathologists from the Department of Pathology at Nanjing Stomatology
Hospital between 2003 and 2011, and ethical approval for this
study was obtained from the Research Ethics Committee of Nanjing
Stomatology Hospital. The HPV status was conﬁrmed by in situ hybrid-
ization (ISH) and p16 immunohistochemistry (IHC) (HPV testing and
the patient information are available upon request). Patients who
were diagnosed with autoimmune or other malignant diseases and
pregnant or lactating individuals were excluded from our experimental
group. No patients underwent preoperative chemotherapy and/or ra-
diotherapy. All of the TSCC tissues were evaluated according to WHO
classiﬁcations by two pathologists.2.2. Immunohistochemistry and immunoﬂuorescence assays
Immunohistochemistry and immunoﬂuorescence assays are
described in the supplementary materials and methods.2.3. Cell culture and reagents
The normal human keratinocyte line HaCaT and the oral squamous
cell carcinoma cell lines HSC-3, Scc-4, Scc-1, HB, Scc-14a, Scc-14b,
OSCC-3, and Cal-27 were cultured in Dulbecco's Modiﬁed Eagle's medi-
um supplemented with 10% FBS (Life Technologies, USA) at 37 °C, 5%
CO2 conditions. Detailed information on the antibodies and reagents
used in this study is provided in Supplementary Table S3.2.4. siRNA transfection and cell viability assay
HaCaT, HSC-3 and Scc-4 cells were seeded in 96-well plates at 5000
cells/well. After the initial transfection of siRNA or negative controls
were place in each well, cells were cultured for 48 h and then
transfected with poly (dA: dT) for 10 h. Cell counting kit-8 (Kumamoto,
Japan) was used for cell viability assay, and the absorbance was mea-
sured at 450 nm by a microplate reader.
2.5. RNA isolation and qRT-PCR
Fresh tissue samples (n= 50) or cell lines were collected. According
to the standard RNA isolation protocol, total RNA was extracted using
Trizol reagent (Invitrogen). Quantitative real-time RT-PCR (qRT-PCR)
was performed, and the expression levels were normalized to GAPDH
for gene expression or U6 for microRNA expression.
2.6. Flow cytometry assay
For the apoptosis analysis, 2 μl of annexin V mixed with 2 μl of
propidium iodide (PI, eBioscience) were added into each tube for
30 min. For the Tregs analysis, FITC-anti-human CD4 (Cat No. 555346,
BD Pharmingen™), PE-Foxp3+ (Cat No. 560046, BD Pharmingen™)
and APC-anti-human CD25 (Cat No. 555434, BD Pharmingen™) were
used to mark Tregs according to the manufacturer's instructions and
quantiﬁed by ﬂow cytometry on a FACS Calibur instrument.
2.7. Preparation of cell extracts and immunoblotting
Prepared cells for western blots were collected with PBS and then
lysed in RIPA bufferwith protease inhibitors and phosphatase inhibitors
(Roche Applied Science). Detailed procedures for immunoblotting are
described elsewhere [20].
2.8. ELISA
Cells were transfected with siRNA, followed by transfection with
poly(dA:dT) or 2′-3′ cGAMP for the indicated time, and then, the super-
natants were collected for the measurement of CCL22 with a MDC
(CCL22) human ELISA kit (Cat No. ab100591, Abcam, USA) according
to the manufacturer's instructions.
2.9. Luciferase assay
HSC-3 cells were transfected with siRNA and reporter plasmid
(CCL22-luc) for 24 h. Subsequently, a second transfection of poly
(dA: dT) or 2′-3′ cGAMP was performed for 10 h. Then, the cells were
collected and a luciferase assay was performed using a Dual-Luciferase
Reporter Assay System (Promega).
2.10. Separation of peripheral blood mononuclear cells and the migration
assay
Approximately 100ml of fresh peripheral blood fromhealthy donors
was collected, and PBMCs were separated by lymphocyte separation
medium according to the manufacturer's instructions. For the cell mi-
gration assay, 12-well plates were used, 500 μl of cell supernatant was
added to the lower chamber and two million human PBMCs were
added to the upper chamber of the inserts with a 5-μm pore size (Cat
No. PIMP15R48, Millipore). In some experiments, 7 μg/ml of anti-
CCL22 neutralizing antibodies (Cat No. ab9847, Abcam, USA) or the
MAPK inhibitor U0126 (Cat No. S1801, Beyotime) were added to the
lower compartment. After migration for 8 h, cells from the lower com-
partment were collected and Tregs was analyzed by ﬂow cytometry.
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Statistical analyses were performed using the Statistical Package for
Social Sciences version 16.0 (SPSS 16.0, SPSS Inc., Chicago, IL, USA) and
the Prism statistical software package (version 5.0, Graphpad Software
Inc.). Unpaired t-tests or Mann–Whitney U tests were used to compare
the two groups, and the differences between more than two groups
were analyzed by the Kruskal–Wallis test. Each experimentwas repeat-
ed at least three times. Differences were considered statistically signiﬁ-
cant when P b 0.05.
3. Results
3.1. The expression of STING is increased in TSCC samples, and HPV+ TSCC
samples contain the activated status of STING
HPVs are difﬁcult to culture in vitro, whichmakes it harder to inves-
tigate its natural infection history with a mouse model. Thus, the exact
molecular evidence for the role of HPV infections in relative cancers is
limited. To evaluate the hypothesis that STING associates with HPV in-
fection to promote tumor formation, we ﬁrst investigated the expres-
sion of STING in TSCC patients. The results of IHC analysis showed that
STING expression showed negative immunostaining in the relative nor-
mal epithelial tissue, weak positive staining in the dysplasia tissue and
strong positive staining in the whole sample. Of note, STING immuno-
staining exclusively occurred in the cytoplasm (Fig. 1A). Moreover,
STING expression was signiﬁcantly upregulated in the tumor, with an
immunohistochemistry (IHC) intensity score over 2 (++) in 31 of 50
TSCC samples, while rare positive staining was detected in relativelyFig. 1. Activated STING is associated with the HPV infection status in TSCC patients. (A) The ex
tibody, diluted × 100. Relatively normal tissues, dysplasia tissues and tumor tissue are shown in
tissues, dysplasia and tumor tissue or (C) in HPV+ and HPV− groups. (***P b 0.001, the P-valu
HPV− groups. Left: IHC of the HPV− groups showed an inactivated status of STING. Right: IH
centage of activated STING in HPV-positive TSCC patients compared with HPV-negative TSCC pnormal epithelial tissue with an IHC intensity score less than 1 (+) in
43 of 50 TSCC samples (Fig. 1B). STING expression in distinct micro-
localization was also statistically analyzed (Supplementary Table S1).
A previous study showed that the presence of high-risk HPV reduces
STING and IFN-κ via its viral protein E2 for immune evasion in cervical
cancer [21]. However,we should note that the E2 proteins are expressed
at early stages of the viral life cycle and have a very short half-life (full-
length BPV1 E2 has a half-life of 40 min) [22]. Interestingly, our results
showed that HPV− and HPV+ TSCC patients showed a similar STING
expression. Thus, we hypothesize that at the early stage of infection,
HPV took advantage of E2 to avoid immune surveillance, but at the
advanced stage of infection, the E2 proteins were signiﬁcantly down-
regulated to restore STING expression; therefore, HPV infection activat-
ed and utilized STING to participate into the formation and progression
of cancer (Fig. 1C).
However, it is known that STING executes anti-infection immunity
through dimerization to activate and relocate to cytoplasmic punctate
structures around the nucleus via dsDNA in the cytoplasm [20,23].
Thus, the status of STING activation was examined. Strikingly, dark
staining around the nucleus was found in 16 of 25 HPV+ TSCC samples,
while diffuse staining over the whole cytoplasm was found in 22 of 25
HPV− TSCC samples (Fig. 1D and E). The phenomenawere in agreement
with previous reports that stated that STING translocated from the
ER or mitochondria to cytoplasmic punctate structures around the
nucleus in response to dsDNA in vitro [23]. The results of these anal-
yses revealed a high correlation between HPV infection and STING
activation, suggesting that activated STING may be a potential factor
in predisposing patients with a HPV infection to accelerating the pro-
gression of TSCC.pression of STING in TSCC (n = 50) was performed by IHC analysis via an anti-STING an-
each dashed box. Scale bar, 150 μm. (B) The IHC scores of STINGwere assessed in normal
e was determined by the Kruskal–Wallis test). (D) Distinct status of STING in HPV+ and
C of the HPV+ groups showed an activated status of STING. Scale bar, 50 μm. (E) The per-
atients was analyzed.
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To investigate the possible mechanisms of activated STING in the
carcinogenesis of HPV+ TSCC patients, we ﬁrst assessed the effects of
STING on cell death. Currently, the correlation between STING and cell
death has been reported by a few studies. B-cell lymphoma 2 (Bcl2)-
associated X protein is a pro-apoptotic molecule and ethanol-induced
ER stress triggers hepatocyte apoptosis by the IRF3-Bax pathway,
which is dependent on STING [24]. Another study indicated that
STING overexpression, but not activation, leads to cell death by activat-
ing caspases in breast cancer cell lines [25]. Liu et al. showed that whenFig. 2. STING activation has no effect on the cell viability or apoptosis of TSCC but promotes the
24-well plates and transfected with 4 μg/ml poly (dA: dT) for the indicated time and immun
calreticulin (ER marker) is red. Scale bar, 10 μm. (B) Three cell lines and HeLa were transfected
poly (dA:dT) or PBS for the indicated time, and cell viability was measured by the CCK-8 assay
value was calculated by Student's t-test. Activated STING promotes the secretion of immunosu
gands by STING activation, including CCL22, IDO, IL-10, FasL, MK, IFN-β and MCP-1 (*P b 0.05,
represent the means ± s.d.endothelial cells from human umbilical veins were stimulated with
cGAMP, the expression of inducible nitric oxide synthase, E-selectin,
and tissue factors were up-regulated and induced endothelial cell
death [6].
We took advantage of polydeoxyadenine-polydeoxythymidine, poly
(dA: dT), as a mimic stimulator of dsDNA from HPV to activate STING,
whichwas similar to the bacterial and virus dsDNA that could be sensed
by STING and dimerized for activation [5]. Because HPV can infect nor-
mal epithelial cells and cancer cells under natural circumstances [26],
poly (dA: dT) transfection was performed on one normal epithelial
cell line and two TSCC cell lines. After the transfection of poly (dA:secretion of immunosuppressive cytokines. (A) HaCaT, HSC-3 and Scc-4 cells were seed in
ostained with the indicated antibodies. Double staining was used; STING is green, and
with 50 nM STING siRNA or negative control for 48 h and then transfected with 4 μg/ml
. (C) Cells were treated as in C, apoptosis was analyzed by a ﬂow cytometry assay. The P-
ppressive cytokines. (D) qRT-PCR validates the expression changes of cytokines and its li-
**P b 0.001, ***P b 0.001 by MannWhitney U test). Data represent the means ± s.d. Data
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(ER) to perinuclear regions and was activated in response to cytoplas-
mic dsDNA ligands in three cell lines (Fig. 2A). Considering that poly
(dA:dT) could trigger multiple pathways, including retinoic acid induc-
ible gene/RIG-like receptors (RLRs), additional transient transfections of
siRNA-STING or control siRNA (Supplementary Fig. S1) were used to
conﬁrm its function after poly (dA:dT) stimulation for 0 h, 8 h, 24 h
and 48 h, but we found that STING activation had no impact on the
cell viability and apoptosis of HaCaT, HSC-3 and SCC-4 (Fig. 2B and C).
To provide further support for the speciﬁc role of STING activation in
TSCC, the HeLa cervical cancer cell line, which is also frequently associ-
ated with HPV, was examined as above. Surprisingly, STING activation
inhibited the cell viability and promoted apoptosis (Fig. 2B and C).
Therefore, these results indicate that STING may exert its pro-
apoptotic function in a tumor type-dependent manner.
3.3. Activated STING enhances the secretion of cytokines, including CCL22,
IDO and IL-10 in TSCC
Because STING shows no impact on cell viability or apoptosis, we in-
vestigated the role of activated STING in the establishment of the tumor
microenvironment. We focused on the cell's nonautonomous route for
STING to promote the depravation of oral lesions. Of note, STING activa-
tion highly induced the expression of cytokines, including CCL22, IDO
and IL-10, in all three cell lines (Fig. 2D, Supplementary Table S2). The
chemokine CCL22 can recruit Foxp3+ Tregs via CCR4 in many types of
cancer tumor microenvironments [27]. The up-regulated expression of
IDO and IL-10 also can induce Tregs expansion and is associated with
a particularly unfavorable clinical outcome [28]. In addition, although
CCL17 could also recruit Tregs, its expression was not affected by
STING activation in HaCaT or SCC4 (Fig. 2D). Tumor cells secrete Fas li-
gand (FasL) to avoid immune surveillance. The up-regulated FasL
mRNA level was observed in three cell lines in response to dsDNA
(Fig. 2D). Midkine (MK) is a pleiotropic growth factor that is often
overexpressed in many cancers [29], and we found that STING activa-
tion signiﬁcantly increased the MK mRNA in TSCC cell lines other than
the HaCaT cell line (Fig. 2D). The levels of interferon-β (IFN-β) and
monocyte chemotactic protein-1 (MCP-1) were reported to be up-
regulated by STING activation in mouse embryonic ﬁbroblasts (MEFs)
[30], but no change was observed in the normal or TSCC cells by RNAi
knockdown of STING, which implied that there were other potential
pathways to induce IFN-β or MCP-1 (Fig. 2D). However, the level of
IFN-β mRNA was up-regulated as previously reported in the HeLa
cell line (Supplementary Fig. S2). Other tumor-related cytokines or re-
ceptors were also examined, such as vascular endothelial growth
factor (VEGF), macrophage inﬂammatory protein-1α (MIP-1α), matrix
metallopeptidase 9 (MMP-9), Fas or IFNAR1. However, no consistent re-
sults were observed in HaCaT, HSC-3 and Scc-4 cells (Supplementary
Table S2). These results indicated that STING activation promoted the
secretion of cytokines, including CCL22, IDO and IL-10, which might be
key driving factors in the development of HPV+ TSCC.
3.4. Activated STING promotes the recruitment of Tregs by up-regulating
CCL22 in HPV+ TSCC patients
Our in vitro data revealed that STING activation could induce CCL22
expression, which had the ability to recruit Foxp3+ Tregs. To establish
clinical evidence of the relationship between STING activation and
Foxp3+ Tregs recruitment in HPV+ TSCC, immunohistochemical stain-
ing of FoxP3+ on the same set of tissue specimens was performed and
analyzed (Fig. 3A). Unsurprisingly, the inﬁltration of FoxP3+ Tregs in
tumor stroma was observed more frequently in HPV+ TSCC patients
than in HPV− TSCC patients (Fig. 3B). Correspondingly, the amount of
FoxP3+ Tregs was signiﬁcantly higher in the STING-activated group
than in the STING-inactivated group (Fig. 3C). We further examined
the role of CCL22 in the recruitment of Tregs in the clinic. Of note, theimmunohistochemistry results showed that the CCL22 immunostaining
was consistent with FoxP3+ immunostaining in TSCC samples. Speciﬁ-
cally, the increased expression of CCL22 in tumor sectionswas exhibited
in HPV+ TSCC patients and the STING-activated group (Fig. 3D–F).
These data suggest that STINGmay be activated to promote the inﬁltra-
tion of Tregs into the stroma by inducing CCL22 expression during
the detection of the dsDNA of HPV. These results demonstrated that
the highly up-regulated Tregs/CCL22 chemokine axis in the STING-
activated TSCC group promoted immunosuppression and participated
in the development of HPV+ TSCC.
3.5. c-Jun is required for elevated levels of CCL22 by STING activation
Currently, there are no effective and targeted therapies for cancer
patients with a HPV infection. The molecular mechanism of CCL22 in-
duction by STING activation could provide a better understanding of
the progression of HPV+ TSCC and help to identify an effective thera-
peutic target. The activation of NF-κB, AP-1 and Jak/STAT is known to in-
duce the gene expression of many chemokines. Thus, we examined the
effects of inhibitors of the NF-κB pathway (PTDC), MAPK/AP-1 pathway
(U0126) and Jak/STAT pathway (AG490) on CCL22 induction by STING.
The results showed that these inhibitors signiﬁcantly suppressed both
the phosphorylation of their independent target protein (Fig. 4A) and
CCL22 expression induced by poly (dA: dT) (Fig. 4B).
There is a possibility that poly (dA: dT) may strongly activate many
cytosolic pathways other than the STING-related pathway to produce
CCL22. To exclude this possibility, a strong agonist of STING, 2′-3′
cGAMP, was used. Transfection of 2′-3′ cGAMP induced STING activa-
tion (Fig. 4C) and IFN-β production in normal epithelial cells and TSCC
cells (Fig. 4D). The level of CCL22 induced by 2′-3′ cGAMP was almost
abrogated by STING knockdown (Fig. 4E). However, the expression of
CCL22 was signiﬁcantly suppressed by U0126 other than PTDC or
AG490 (Fig. 4 F). These results demonstrate that STING activation up-
regulated the expression of CCL22 preferentially via the MAPK/AP-1
pathway, but not the NF-κB pathway or Jak/STAT pathway.
To verify our ﬁndings, c-Jun and c-Fos, the critical elements of AP-1
complexes [31], were analyzed. The results showed that STING activa-
tion increased the phosphorylation of c-Jun and c-Fos together with
CCL22 production in a time-dependent manner (Fig. 4G). Interestingly,
the silencing of c-Jun, but not c-Fos, remarkably inhibited themRNA and
protein induction of CCL22 (Fig. 4H–J). To provide further support for
the role of AP-1 in the CCL22 production by STING activation, we next
investigated the transcriptional activity of c-Jun and c-Fos by the lucifer-
ase assay. We found that c-Jun strongly promoted the initiation of the
gene transcription of CCL22, while c-Fos had no effect (Supplementary
Fig. S3). Together, these results implied that c-Jun was essential for
the CCL22 production induced by STING activation and that the c-Jun
inhibitor could be a potential clinical protocol for the treatment of
HPV+ TSCC patients.
3.6. miR-27 targeted STING and affected CCL22 expression and Tregs
recruitment
Because of the immunosuppressive function of activated STING in
HPV+ TSCC, the mechanism to control the extent and strength of
STING activation needed to be explored. Dysregulated miRNAs play a
role in almost all aspects of cancer biology, such as angiogenesis, inva-
sion/metastasis, apoptosis, proliferation, and the microenvironment
[32]. Thus, several predicted microRNAs (miRNAs) that directly target
the 3′ untranslated region (UTR) of STING were screened by miRWalk
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/). Compara-
tive analysis by 5 prediction programswere used to conﬁrm the accura-
cy of the prediction; 12 predictedmiRNAswhich play important roles in
cancer were selected, and their levels were determined in normal epi-
thelial, dysplasia and tumor tissues from fresh tissues of TSCC patients
(n = 50). The results showed that ﬁve miRNAs levels, including miR-
Fig. 3. The presence of CCL22/Tregs correlates with the poor prognosis of TSCC patients. (A) Foxp3-positive Tregs were determined by immunohistochemical staining via an anti-Foxp3
antibody (B) in HPV+ and HPV− groups, *P b 0.05, the P-value was determined by an unpaired Student's t-test. (C) The IHC score of Foxp3-positive Tregs was also assessed in STING-
inactivated and -activated groups (*P b 0.05, the P-value was determined by an unpaired Student's t-test). (D–F) Similarly, CCL22 was also determined by IHC in the HPV+ and HPV−
groups and in STING-inactivated and activated groups (*P b 0.05, ***P b 0.001 by t-test).
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down-regulated trends fromnormal tissue to cancerous tissue, suggest-
ing a correlation of the miRNAs with the up-regulation of STING
(Fig. 5A). Moreover, according to the widely different expression of
miRNAs in normal tissue, miR-27a/b was found to be the most signiﬁ-
cantly abundant among the miRNAs in normal tissue (Fig. 5B), and the
ratio of miR-27a/miR-27b was 3:1. Therefore, we next determined the
possibility that STING served as a target of miR-27a/b. The putative
targeting sequences in the 3′UTR of STING predicted by TargetScan
(http://www.targetscan.org) showed that the two miRNAs have the
same target sites. We found that the enforced expression of miR-27
(miR-27a: 27b = 3:1, the mimic of natural expression ratio) reduced
both STING mRNA and protein expression in the TSCC cell line
(Fig. 5C). Meanwhile, one normal epithelial cell line and seven TSCC
cell lines were examined by qPCR analysis, and the results showed
that the level of miR-27a/b was reduced inmost cancer cell lines. Corre-
spondingly, STING expression in the TSCC cells was generally increased
compared to the normal cell line (Fig. 5D). These data indicated that
miR-27 was involved in the regulation of STING expression in TSCC
cell lines.
We hypothesized that miR-27 could impair STING activation-
induced CCL22 to recruit Tregs inﬁltration. To test the hypothesis,
HSC-3 cells were transfected with miR-27 (miR-27a: miR-27b = 3:1),
and then, STING was activated by poly (dA: dT) or 2′-3′ cGAMP. The re-
sults revealed that miR-27 effectively suppressed both CCL22 mRNA
and protein levels (Fig. 5E).Moreover, the peripheral bloodmononucle-
ar cells (PBMCs) that were freshly isolated from healthy donors weretreated with the indicated culture media from HSC-3 for the transwell
assay (Fig. 5F), and FoxP3+CD4+CD25+ Tregswere analyzed. Expected-
ly, STING activation promoted themigration of Tregs,while overexpres-
sion of miR-27 decreased the migratory activity of Tregs. Furthermore,
an anti-CCL22 neutralizing antibody and the inhibitor of the MAPK/
AP-1 pathway (U0126) signiﬁcantly impaired the Treg cell migratory
activity (Fig. 5G). These data indicated that the down-regulated miR-
27 contributed to the increased CCL22 and Tregs recruitment via the
enhancement of STING activation in HPV+ TSCC.
4. Discussion
The scarcity of the HPV infection-mouse model limited the investi-
gations on its complex mechanisms of carcinogenesis. Apart from its
viral protein, in this study, we provided new clues regarding HPV infec-
tions in carcinogenesis and dissected the role of activated STING in
the establishment of the HPV+ TSCC microenvironment and found
that HPVs hijack STING to induce CCL22 to recruit Tregs and that the
down-regulated miR-27 ampliﬁes the interaction among STING/
CCL22/Tregs in the carcinogenesis of HPV+ TSCC patients and brings
the dark side of STING in cancer to light (Fig. 6).
Recently, more than 10 DNA sensors have been found to connect
with the DNA sensing and immune defense, including Toll-like recep-
tors (TLRs), RIG-like receptors (RLRs), NOD-like receptors (NLRs) and
the enzyme cyclic GMP-AMP synthase (cGAS). As a newly discovered
molecule in DNA sensing, the activation of the STING-IFN pathway is
critical to limit the replication of DNA viruses, including HIV or HSV-1
Fig. 4. STING activation up-regulates CCL22 expression via c-Jun. (A) HSC-3 cells were seeded in 6-well plates and pretreated with PTDC, U0126 or AG490 for 30 min and were then
transfected with 4 μg/ml poly (dA:dT) for 5 h. Cell lysates were collected and a western blot was performed. GAPDH in the corresponding cell lysate was used as a loading control.
(B) HSC-3 cells were incubated with different inhibitors and then activated STING by 4 μg/ml poly (dA:dT) for 12 h. ELISA was used to assess the impact of inhibitors on the expression
of CCL22 by STING activation. (C) HaCaT, HSC-3 and Scc-4 cells were seeded in 24-well plates and transfected with 10 μg/ml 2′-3′ cGAMP for 0 h and 8 h, and then, they were immuno-
stainedwith the indicated antibodies. STING is green, and calreticulin is red. Scale bar, 10 μm. (D and E) HSC-3 cells were transfectedwith 50 nM STING siRNA or negative control for 48 h,
followedby transfectionwith 10 μg/ml 2′-3′ cGAMP for 12h. The level of IFN-β andCCL22were determined (**P b 0.01, ***P b 0.001, determined by t-test). (F) Using the same treatment in
B, cells were transfectedwith 10 μg/ml 2′-3′ cGAMP for 12 h, and the CCL22 level was estimated by ELISA. (G) Thirtyminutes after pretreatmentwith U0126, HSC-3 cells were transfected
with 10 μg/ml 2′-3′ cGAMP for the indicated time, andwhole-cell extractswere prepared forwestern blot. (H) The siRNAassay (negative control siRNA or c-Jun/Fos-siRNA)wasperformed
for 24 h, and the proteinswere collected after 48 h for western blot. (I and J) Q-PCR and ELISA assays were performed for the effects of c-Jun and c-Fos on the induction of CCL22 by STING
activation (**P b 0.001 by t-test). Data represent the means ± s.d.
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CCL20, are induced by STING activation to execute anti-infection immu-
nity or autoimmunity. There have been a few studies about the role of
STING in cancer, including breast cancer [25], non-small cell lung cancer
(NSCLC) [8] and lymphoma [33]. For example, nuclear DNA-associated
entities from dying cells were determine and uptake by dendritic cells
(DCs)were found to occur in a STING-dependent manner that efﬁcient-
ly primed IFN-dependent CD8+ T cell responses to tumor Ags and
promoted antitumor responses [34]. Jirik et al. showed that STING acti-
vation by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) or 2′-3′
cGAMP can mediate M2-like TAM re-education towards an M1 pro-
inﬂammatory phenotype in NSCLC [8]. However, the immunosuppres-
sive role in DNA sensing via STING has been found, and Mellor et al.
showed that selective DNA uptake and sensing via STING in CD11b+
dendritic cells (DCs) by apoptotic cells induced IDO and suppressedTh1 responses though Treg responses [35]. In addition, they also indicat-
ed that selective STING activation in hematopoietic cells could suppress
experimental autoimmune encephalitis (EAE) by inducing dominant T
cell regulatory responses via the STING/IFN/IDO pathway [10]. Another
study reported that inﬂammation-driven skin carcinoma wasmediated
by activated STING [4], which suggested that STING functioned not only
as a proinﬂammatory mediator but also as an immunosuppressive
adapter. We emphasized the anti-inﬂammatory aspects of STING in
TSCC with HPV infection.
In the present study, we observed increased STING expression in
OSCC patients and cell lines. Notably, limited studies in breast cancer
showed a decreased expression of STING by immunohistochemistry
and Q-PCR [25]. Thus, there was a possibility that STING functioned dif-
ferently in distinct types of cancer. Although investigations have found
that normal tissue and cancerous tissue have signiﬁcantly different
Fig. 5.miR-27 controls CCL22, which recruits Tregs by modulating STING activation. (A) microRNAs that targeted STING were measured in fresh TSCC tissue (n = 50) samples by qPCR.
(B) The results are shown as different levels of ﬁve microRNAs in normal tissue. (C) Putative miR-27a/b binding sites in the 3′ UTR of STING. HSC-3 cells were transfected with 50 nM of
miR-27a/bmimetic for 24 h, and the STINGmRNA level was determined by qPCR and normalized to GAPDH. ***P b 0.001 (MannWhitney test). The STINGprotein level was determined by
Western blot. (D) ThemiR-27a,miR-27b and STING expression inHaCaT and TSCC cellswere determinedbyqPCR (*P b 0.05 by t-test). (E)HSC-3 cellswere transfectedwith 20 nMmiR-27
for 48 h and then incubated or not with U0126 for 30min and transfected with 4 μg/ml poly (dA: dT) or 10 μg/ml 2′-3′ cGAMP. The supernatants were collected for ELISA. Statistical sig-
niﬁcancewas analyzed by the t-test (*P b 0.05, **P b 0.01 and ***P b 0.001). (F and G) The supernatants were collected from two transfections of the indicated reagents, and 2 × 105 freshly
isolated human PBMCwere used for transwell assay. After 8 h ofmigration, cells in the lower compartmentwere harvested and CD4+CD25+Foxp3+ Tregswere estimated by ﬂow cytom-
etry assay (*P b 0.05, **P b 0.01 by t-test). Data represent the means ± s.d.
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cancer remains unknown.Here, we illustrated a reverse relationship be-
tween STING and microRNA expression. miR-27, which regulates the
gene controlling STING transcription by targeting its 3′ UTR and as
well as its degradation in vitro, gradually decreased during the progres-
sion of OSCC patients. Correspondingly, the results from cell lines also
showed a lower level of miR-27 in different OSCC cell lines than that
in normal keratinocytes. Sunthamala et al. showed that STING andIFN-κ could be attenuated by the presence of high-risk HPV via its
viral protein E2 for immune evasion in cervical cancer [21]. However,
E2 proteins are expressed at early stages of the viral life cycle and
have a very short half-life (full-length BPV1 E2 has a half-life of
40 min) [22]. Furthermore, our results showed that STING expression
exhibited no difference between HPV+ and HPV− samples in tongue
squamous cell carcinoma. More importantly, we found that STING func-
tioned differently in distinct types of tumors and had a different impact
Fig. 6.Model summarizing the protumorigenic nature of STING in themicroenvironment of HPV+ TSCC patients. mir-27 was down-regulated during the development of TSCC, leading to
the high expression of STING, which could be activated by HPV infection, and induced a series of immunosuppressive cytokines for the establishment and maintenance of the TSCC mi-
croenvironment in HPV+ TSCC patients.
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tivate and utilize STING to participate in carcinogenesis. In fact, we
noted that the activated status, as opposed to the expression, of STING
might contribute to the HPV-related TSCC. In HPV+ TSCC patients,
STING formed cytoplasmic punctate structures around the nucleus,
whichwas consistentwith the features of STING activation, as described
previously [5]. Thus, the phenomenon implicated that STING was acti-
vated byHPV in TSCC patients, suggesting that there could be a different
mechanism of HPV, different from HPV integration, during tongue
carcinogenesis.
Currently,more research on possiblemolecularmechanisms of HPV-
induced carcinoma are urgently required. Potentialmechanisms includ-
ed the distinct sensitivity to radiation, chemotherapy or smoking habits
of patients.More importantly, a HPV infection could change the status of
the host immune system [13]. Many studies showed increasing levels of
Foxp3 mRNA and Foxp3+ regulatory T cell (Tregs) inﬁltration in HPV+
tumors, but the mechanism of Treg inﬁltration in HPV+ tumors has
been unclear. Although both CCL22 and CCL17 were able to recruit
Tregs to participate in the progression of cancer, in this study, the che-
mokine CCL22, but not CCL17, was remarkably up-regulated in all
three cell lines by STING activation. Additionally, the clinical data sup-
plied strong evidence that more CCL22 and Foxp3+ Tregs are present
in TSCC patients with HPV infection, which could supply evidence that
activated STING might activate CCL22 for the recruitment of Tregs in
TSCC patients.
Apart from poly(dA:dT), bacterial cyclic dinucleotides and human
endogenous messenger 2′-3′cGAMP were demonstrated to effectively
and directly activate STING, but the latter was a much more potent li-
gand of STING than other bacterial cyclic dinucleotides [3]. Although
c-Jun and c-Fos play an essential role in tumorigenesis, c-Jun ismore im-
portant in the development of skin and liver tumors [36]. Colburn et al.
reported that transgenic mice with mutant c-jun impaired c-Jun/AP-1
activity and were resistant to the development of chemically induced
papilloma [37]. Upon transfection of 2′-3′cGAMP into HaCaT or two
TSCC cell lines, we found that STING activated theMAPK/AP-1 pathway
to phosphorylate c-Jun and c-Fos, but enabled the transcription of
CCL22 in a c-Jun-dependent manner and recruited Tregs. Our results
highlighted the function of c-Jun in the progression of HPV+ TSCC and
suggested that an inhibitor of c-Jun would be a promising therapeutic
drug candidate. Finally, Li et al. reported the pivotal roles of 2′-3′
cGAMP in immune adjuvant effects in a STING-dependent manner
[38]. However, our results indicated that activated STING by 2′-3′
cGAMP could promote the establishment of the TSCC microenviron-
ment by immunosuppressive cytokines, e.g., FasL, IL-10, IDO andCCL22, and recruitment of Tregs, suggesting that the immune adjuvant
effects of 2′-3′cGAMP should cause us to reconsider its application, at
least in HPV+ TSCC patients.
5. Conclusions
In sum, these ﬁndings indicated that HPVs hijack STING to induce
CCL22 to recruit Tregs and that down-regulated miR-27 ampliﬁes the
interaction among STING/CCL22/Tregs in HPV+ TSCC patients, suggest-
ing that STING is versatile in different circumstances that inﬂuence im-
mune responses to DNA and that the STING activation pathway might
be considered to be an antitumor therapeutic target in HPV-related
carcinogenesis.
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